Hormone therapy is a type of prostate cancer treatment that stops your body from making these hormones or letting them reach cancer cells. The cells then die or grow more slowly. It’s also known as androgen deprivation therapy (ADT). You may get it on its own, but you’ll likely also ...
Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001; 61(15): 2177–92Katherine A., HarrisDavid M., Reese. (2001) Treatment Options in Hormone-Refractory Prostate Cancer. Drugs 61 , 2177-2192 /...
For patients with metastatic hormone-sensitive prostate cancer, what are the treatment options? Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type or stage of prostate cancer in which the cancer has spread outside of the prostate—that's the metastatic t...
While experts debate the best way to use hormone therapy for prostate cancer, they do agree on the strides we've made in treating this disease. Improved detection and treatment -- like hormone therapy -- have really changed the picture. ...
"Currently, treatment options for men with advanced prostate cancer are limited, however I hope that after we have conducted larger studies to confirm our findings, we will see this change and we will be able to treat these patients very differently, using radiotherapy as standard to target drug...
Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment Luteinizing hormone-releasing hormone (LHRH) analogues play a pivotal role in hormonal therapy regimens for the treatment of prostate cancer. Hormonal ther... H Akaza - 《Pharmacology》 被引量: 40发表: ...
However, NICE said these potential benefits were outweighed by the cost of the treatment and how it might limit patients' future treatment options. This is because either enzalutamide or another prostate cancer drug, called abiraterone (Zytiga), can currently only be offered once during a patient'...
At the present time in Japan, the androgen ablation therapy, such as the surgical castration, estrogen therapy, antiandrogen therapy and LHRH agonist therapy, is mainly used for the treatment of advanced prostate cancer as well as for early prostate cancer. Ten to twenty percent of advanced pros...
Therefore, this single modality should be limited to the most aggressive situations when no local treatment is planned.Single hormonal treatment for nonmetastatic advanced prostate cancer appears to be limited to the few patients unfit or unwilling for a local treatment and having a high prostate-...
There are few treatment options for prostate cancer once it becomes hormone refractory, with a mean life expectancy of 9-12 months. During the period 1997-... M Shabbir,J Love,B Montgomery - 《Oncology Reports》 被引量: 36发表: 2008年 997 RISK FOR RECURRENT PROSTATE CANCER INCREASES WITH ...